|
|
|
| Effect of Valsartan on coronary restenosis after coronary intervention |
| LIU Yingzhi1 XIONG Zhenyu2 XIONG Longgen3 |
1.Department of Clinical Medicine, Guangzhou Medical University, Guangdong Province, Guangzhou 510000, China;
2.Department of Cardiology, the Second People′s Hospital of Guangdong Province, Guangdong Province, Guangzhou 510000, China;
3.Department of Cardiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangdong Province, Guangzhou 510000, China |
|
|
|
Abstract Objective To investigate the effect of Valsartan on coronary restenosis after coronary intervention. Methods A total of 98 patients who underwent coronary intervention and stent placement at the Second Affiliated Hospital of Guangzhou Medical University from January 2016 to November 2017 were randomly divided into experimental group (n = 49) and control group (n = 49) according to the principle of randomly selected case numbers. The control group received routine treatment. The experimental group were treated with Valsartan Capsules on the basis of routine treatment. At the same time, 30 patients who underwent coronary angiography without stenting were selected as negative control group. The echocardiographic EF values, the occurrence of adverse cardiovascular events and coronary restenosis, and the contents of endothelin-1 (ET-1), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), lipoprotein-related phospholipids and enzyme A2 (LP-PLA2) were analyzed in the three groups of patients. Results In the experimental group, there were 5 cases with coronary restenosis, with an incidence of 10.20%. In the control group, coronary restenosis occurred in 13 cases with an incidence of 26.53%, and the difference between the two groups was statistically significant (P < 0.05). The ET-1, hs-CRP, IL-6, LP-PLA2 and EF values of the three groups 4 weeks after surgery were compared with those before surgery, and the differences were statistically significant (P < 0.05). Four weeks after surgery, the differences of ET-1, hs-CRP, IL-6, LP-PLA2 and EF values in the experimental group, the control group and the negative control group were statistically significant (P < 0.05). Four weeks after surgery, experimental ET - 1, the hs-CRP, IL-6, LP-PLA2 were compared with control group, negative control group, and the differences were statistically significant (P < 0.05), while the control group compared with negative control group, there was no statistically significant difference (P > 0.05). Echocardiographic EF values of the experimental group, the control group and the negative control group were compared with those of the same group 4 weeks after surgery, and the differences were statistically significant (P < 0.05). EF values of the experimental group compared to control group, the difference was statistically significant (P < 0.05). The incidence of adverse cardiovascular events in the experimental group were less than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion After coronary intervention, valsartan can effectively reduce the incidence of coronary restenosis, reduce the content of endothelin and inflammatory cytokines, and significantly improve the occurrence of adverse cardiovascular events and echocardiographic EF values.
|
|
|
|
|
|
[1] Sharmak K，Mathur M，Gupta R，et al. Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease[J]， Indian Heart J，2013，65（3）：250-255．
[2] 赵伟，李婷婷，李莹.冠心病患者炎性因子水平与急性冠状动脉综合征的相关性分析[J].中华老年心脑血管病杂志，2014，16（2）：207-208．
[3] 张赟，许丽雯．缬沙坦联合美托洛尔治疗原发性高血压合并冠心病的疗效观察[J].中西医结合心脑血管病杂志，2016，14（2）：173-175．
[4] Cassese S，Byrne RA，Tada T，et al. Incidence and predictors of restenosis after coronary stenting in 10004 patients with surveillance angiography [J]. Heart，2014，100（2）：153-159.
[5] 张安兴.不同剂量阿托伐他汀钙预防颈动脉粥样硬化患者脑梗塞的作用[J].心血管康复医学杂志，2011，20（3）：256-257.
[6] Altabas V. Diabetes，Endothelial Dysfunction， and Vascular Repair： What Should a Diabetologist Keep His Eye on? [J]. Int J Endocrinol，2015，2015：848272.
[7] 何荣华，岳新荣．缬沙坦对冠心病患者血清hs-CRP和颈动脉斑块的影响[J].安徽医药，2015，19（2）：382-384．
[8] 张浩，孙文文，施良，等.MARK信号通路介导血管紧张素Ⅱ对人外周血早期内皮祖细胞的功能调节[J].中国急救医学，2015，35（12）：1134-1138.
[9] 马志强，马韬，刘力，等．缬沙坦对冠心病患者颈动脉斑块及血清高敏C反应蛋白的影响[J]．临床心血管病杂志，2014，30（2）：135-137．
[10] Tian M，Sheng L，Huang P，et al. Agonistic autoantibodies against the angiotensin AT1 receptor increase in unstable angina patients after stent implantation [J]. Coron Artery Dis，2014，25（8）：691-697.
[11] 晓龙，邱健.不同剂量缬沙坦对缺血性心肌病心力衰竭疗效观察[J].河北医药，2013，35（7）：1003-1005．
[12] Britton KA，Gaziano JM，Djoussé L. Normal systolic blood pressure and risk of heart failure in US male physicians [J]. Eur J Heart Fail，2009，11（12）：1129-1134.
[13] Rajendran P，Rengarajan T，Thangavel J，et al. The vascular endothelium and human diseases [J]. Int J Biol Sci，2013，9（10）：1057-1069.
[14] 姚志灵，陈亮，王欣丽.不同糖代谢状态冠心病患者氧化应激的研究进展[J].中国医药导报，2015，14（26）：46-49．
[15] 李军，徐朝，郭志强，等.冠状动脉病变程度与超敏C反应蛋白、尿白蛋白/肌酐比值的相关性[J].武警后勤学院学报：医学版，2015，24（10）：806-807.
[16] Bentzon JF，Otsuka F，Virmani R，et al. Mechanisms of plaque formation and rupture [J]. Circ Res，2014，114（12）：1852-1866.
[17] 韩根根.尿清蛋白肌酐比值与冠心病危险因素的研究进展[J].中国医药导报，2014，11（8）：31-34．
[18] 谈红，王雪，李晓燕，等.培哚普利对冠心病患者循环血内皮祖细胞及血管内皮功能的影响[J].中国循环杂志，2015，30（1）：22-25.
[19] Zhang L，Xu Q. Stem/Progenitor cells in vascular regeneration [J]. Arterioscler Thromb Vasc Biol，2014，34（6）：1114-1119.
[20] 郑晓丽.缬沙坦治疗慢性心竭观察[J].临床军医杂志，2010，38（4）：562-563．
[21] Delva P，Degan M，Vallerio P，et al. Endothelial progenitor cells in patients with essential hypertension [J]. J Hypertens，2007，25（1）：127-132. |
|
|
|
